U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07148830) titled 'Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.' on Aug. 17.
Brief Summary: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high rates of local recurrence and distant metastasis.
Recent evidence suggests that mesopancreatic excision (TMpE) may improve R0 resection rates, reduce local recurrence, and enhance overall survival compared to standard pancreatoduodenectomy. However, most existing studies are retrospective with heterogeneous patient populations and surgical techniques.
This prospective study aims to evaluate the impact of mesopancreatic excision, a surgical technique involving the meticulo...